Overview

• Humacyte Q3 net income beats analyst expectations, despite a slight miss in operating income

• Company's Q3 revenue increased significantly due to Symvess sales

Outlook

• Humacyte plans supplemental BLA filing for ATEV dialysis indication in second half of 2026

• Company aims to start first-in-human CTEV study for CABG in 2026

• Humacyte expands intellectual property with new patent for bioengineered esophagus

Result Drivers

• SYMVESS SALES GROWTH - Significant increase in Symvess sales driven by hospital approvals and inclusion in U.S. Defense Logistics Agency’s ECAT

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Humacyte Inc is $3.50, about 63.4% above its November 11 closing price of $1.28

Press Release: ID:nGNX54t6bm

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)